Rentschler Biopharma highlighted progress and expansion at its U.S. Milford, Massachusetts facility, describing a transition into a new phase of multi-product growth. The company said it is onboarding diverse client programs and adding capacity for late-stage development and manufacturing operations. Rentschler reported that its newest production line became fully operational in 2024, adding 22,000 square feet of cleanroom space and expanding global cGMP capacity. The expansion includes four 2,000 L single-use bioreactors supporting multiple modalities. The site supports a broad range of therapeutic areas including oncology, hematology, and cardiovascular, and the company stated it has introduced seven new products to the facility over the past two years. The manufacturing expansion matters for developers because it increases supply resilience for clinical and commercial biologics as CDMO selection tightens and timelines for tech transfer remain a gating factor.